US Peptide Science Research Team
October 31, 2026
Three major Phase 3 clinical trials published in September 2026 provide comprehensive efficacy and safety data for retatrutide, a novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways. These trials—conducted across multiple international sites and involving over 4,000 participants—represent the most extensive clinical evaluation of retatrutide to date and establish its efficacy profile in adults with obesity and type 2 diabetes.
The Phase 3 program consisted of three parallel, double-blind, placebo-controlled trials with distinct participant populations:
TRIUMPH-2 enrolled 1,152 adults with both obesity (BMI ≥27 kg/m²) and type 2 diabetes on stable glucose-lowering therapy. Participants had a mean baseline BMI of 38.2 kg/m² and HbA1c of 7.71%, with median obesity and diabetes durations of 21 and 5.6 years, respectively. Participants received once-weekly subcutaneous injections of retatrutide (4 mg, 9 mg, or 12 mg) or placebo for 80 weeks, with the primary endpoint being percentage bodyweight change at week 80 for the 9 mg and 12 mg doses versus placebo.
TRANSCEND-T2D-1 evaluated retatrutide as monotherapy in 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone (HbA1c 7.0–9.5%). This 40-week trial assessed baseline HbA1c changes as the primary endpoint, with bodyweight reduction as a key secondary measure. Mean baseline HbA1c was 7.9% and BMI was 35.8 kg/m².
The NEJM-published obesity trial (referenced as the primary obesity efficacy study) enrolled 2,339 participants with obesity without diabetes across multiple centers, examining weight loss as the primary outcome over 80 weeks. This trial also included prespecified subgroup analyses in 574 participants with knee osteoarthritis (measuring WOMAC pain scores) and 243 with obstructive sleep apnea (measuring apnea–hypopnea index).
Retatrutide demonstrated dose-dependent weight loss across all trials. In the thelancet.com TRIUMPH-2 trial, mean bodyweight reduction at week 80 was:
Estimated treatment differences versus placebo were −6.9 percentage points (95% CI −8.7 to −5.1) for the 4 mg dose, −11.8 percentage points (−13.7 to −9.8) for 9 mg, and −13.8 percentage points (−15.8 to −11.8) for 12 mg (all p<0.0001).
The nejm.org NEJM-published Phase 3 trial in adults with obesity without diabetes showed more pronounced weight loss:
This difference reflects the younger age and lower baseline comorbidity burden in the obesity-only population compared to the obesity-plus-diabetes cohort. Notably, 59.5% of participants receiving retatrutide 12 mg no longer met BMI criteria for obesity at trial conclusion, representing substantial clinical remission of the obese phenotype.
In the pubmed.ncbi.nlm.nih.gov TRANSCEND-T2D-1 trial, mean bodyweight reduction from baseline to week 40 was:
While TRIUMPH-2 prioritized bodyweight as the primary endpoint, HbA1c improvements were documented as secondary outcomes. The trial demonstrated clinically meaningful reductions in glycemic control across retatrutide-treated groups, with dose-dependent improvements.
In the monotherapy trial, mean HbA1c reduction from baseline to week 40 was:
Estimated treatment differences versus placebo were −0.88% (95% CI −1.18 to −0.59) for 4 mg, −1.04% (−1.32 to −0.76) for 9 mg, and −1.12% (−1.39 to −0.85) for 12 mg (all p<0.0001). These reductions exceeded 1 percentage point for the higher doses, consistent with thresholds for clinically significant glycemic improvement in type 2 diabetes management.
In the NEJM obesity trial, retatrutide demonstrated effects beyond weight and glucose metrics. Among 574 participants with knee osteoarthritis, WOMAC pain score reductions (hybrid estimand) were:
Among 243 participants with obstructive sleep apnea, apnea–hypopnea index reductions (hybrid estimand) were:
These findings suggest retatrutide's weight-loss effects translate into measurable improvements in obesity-related comorbidities.
Gastrointestinal side effects were the predominant safety concern across all trials. In TRIUMPH-2, diarrhea incidence was:
Nausea incidence was:
In TRANSCEND-T2D-1, gastrointestinal events were generally mild to moderate and subsided over the 40-week treatment period. No severe hypoglycemia was reported in this monotherapy trial.
In TRIUMPH-2, hypotension (defined as systolic blood pressure <90 mmHg or symptomatic hypotension) occurred in:
Dysesthesia (abnormal skin sensation) was reported in:
The clinical significance of dysesthesia reports requires further investigation, as this finding was not emphasized in earlier Phase 2 data and warrants monitoring in ongoing surveillance.
Permanent discontinuation rates in TRIUMPH-2 were:
The elevated discontinuation rate in the 9 mg group warrants clinical attention and may inform dose-selection strategies in clinical practice. In TRANSCEND-T2D-1, discontinuation rates were lower at 2–5% across retatrutide groups and 0% with placebo.
Across the three trials, seven deaths were reported (two in TRIUMPH-2 4 mg group, three in 9 mg group, one in 12 mg group, one in placebo group; two additional deaths in TRANSCEND-T2D-1, both in the 4 mg group). Investigators deemed all deaths unrelated to the study intervention. The small absolute numbers and investigator assessments do not suggest a drug-related mortality signal, though ongoing pharmacovigilance remains essential.
Retatrutide's triple agonism at GIP, GLP-1, and glucagon receptors distinguishes it mechanistically from existing GLP-1 receptor agonists (such as semaglutide or tirzepatide). The addition of GIP and glucagon receptor signaling may enhance weight loss efficacy and metabolic improvement, though the Phase 3 data do not directly isolate the contribution of each pathway.
The dose-dependent efficacy observed across all trials supports the hypothesis that higher receptor occupancy yields greater therapeutic benefit, at least up to the 12 mg dose tested. However, the increased adverse event burden at higher doses—particularly the 12% discontinuation rate at 9 mg in TRIUMPH-2—suggests a potential therapeutic window and emphasizes the importance of individualized dose assessment.
While these trials provide robust Phase 3 evidence, several limitations warrant acknowledgment:
The Phase 3 efficacy data from TRIUMPH-2, TRANSCEND-T2D-1, and the NEJM obesity trial establish retatrutide as a pharmacologically active triple receptor agonist with substantial effects on bodyweight reduction (17.6–25.0%), glycemic control (HbA1c reductions of 1.1–1.9%), and obesity-related comorbidities. The safety profile is consistent with GLP-1 receptor agonist class effects, dominated by mild-to-moderate gastrointestinal events. Elevated discontinuation rates at higher doses and emerging reports of dysesthesia warrant careful monitoring in clinical use and post-marketing surveillance. These results support retatrutide's potential role in the therapeutic landscape for obesity and type 2 diabetes, pending regulatory approval and longer-term outcome data.
thelancet.com published the TRIUMPH-2 trial in September 2026, demonstrating retatrutide efficacy in adults with obesity and type 2 diabetes. nejm.org published the Phase 3 obesity trial with extended subgroup analyses in knee osteoarthritis and obstructive sleep apnea. pubmed.ncbi.nlm.nih.gov hosts the TRANSCEND-T2D-1 monotherapy trial demonstrating retatrutide's efficacy as a single agent for inadequately controlled type 2 diabetes.
Source research
Referenced literature: The Lancet, New England Journal of Medicine, PubMed Central. No direct link is attached to this article.